Acquisition of Three Companies, Including GC Green Cross Subsidiary, for 5.7 Trillion Won

Global pharmaceutical company Eli Lilly has designated new infectious diseases and vaccines as future growth engines, expanding beyond its main areas of metabolic diseases, oncology, and immunotherapy, and is proactively securing a pipeline in these new fields.


According to the industry on May 28, Lilly recently decided to acquire three vaccine-specialized companies: Curevo, LimmaTech Biologics, and Vaccine Company. The total acquisition amount reaches $3.83 billion (approximately 5.7562 trillion won). This move by Lilly is considered a prime example of how big pharma, which has secured substantial financial resources following the unprecedented success of GLP-1 (glucagon-like peptide-1) drugs for obesity and diabetes, is reinvesting its capital.

While many multinational pharmaceutical companies have focused research funding on the development of highly profitable chronic disease and oncology drugs, there is now a renewed focus on the importance of infectious disease prevention and the explosive growth potential of next-generation vaccine technologies. The industry is witnessing a shift from the traditional approach of treating the consequences of diseases after their onset to preventive medicine that proactively blocks the origin of diseases, marking the beginning of a broader movement of capital into this area.

Why Industry-Leading Lilly in Obesity and Metabolic Diseases Is Now Targeting Vaccines View original image

Decades of epidemiological research have revealed that common infections can lead to severe diseases such as neurological disorders, cancer, or infertility years later. Furthermore, the global threat posed by antibiotic-resistant superbugs, which cannot be treated with existing antibiotics, is driving renewed recognition of proactive vaccination as the only viable alternative. In October last year, Lilly hired Dr. Peter Marks, former director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), as Head of Infectious Diseases. The series of vaccine company acquisitions is interpreted as a strategic response to this paradigm shift in the industry.


Among the acquired companies, the Korean industry is paying particular attention to Curevo. Lilly plans to pay Curevo shareholders up to $1.5 billion (approximately 2.25 trillion won) in cash, including upfront and milestone payments. Curevo is a U.S.-based subsidiary established in November 2017 through joint investment with U.S. experts, aiming for GC Green Cross’s entry into the global vaccine market. The company is developing Amezosvataine, a next-generation shingles vaccine, and in October last year, GC Green Cross signed a contract manufacturing agreement with Curevo to supply the vaccine after its commercialization.


Analysts say that the combination of Lilly’s massive capital and global commercialization network has significantly increased the likelihood of successful final development of the vaccine. If the existing contract manufacturing agreement is maintained, a leading global vaccine could be exported overseas based on domestic production infrastructure.


In addition, Lilly will acquire LimmaTech Biologics, which develops vaccines against antibiotic-resistant bacterial pathogens, for up to $780 million (approximately 1.1715 trillion won). Vaccine Company, which uses virus-like particle technology to induce sustained immune responses, will be acquired for up to $1.55 billion (approximately 2.3281 trillion won).



An industry official stated, "This series of acquisitions by Lilly indicates that big pharma’s efforts to strengthen infectious disease response capabilities are in full swing. Based on stable cash generation, the strategy of absorbing biotech firms with innovative platform technologies to secure global leadership in preventive medicine is expected to intensify competition within the pharmaceutical and biotech industries."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing